Table 4.
Sensitivity, specificity, and PPV of anti-citrullinated antibodies for overall JIA population and JIA subtypes
| |
Sensitivity (%) |
Specificity (%) |
PPV (%) |
|---|---|---|---|
| With 95% CI | With 95% CI | With 95% CI | |
|
Anti-citrullinated type II collagen |
|
|
|
|
Antibodies (> 3.03OD) |
|
|
|
| Overall (n=95) |
25.8 (17.4-36.4) |
86.2 (67.4-95.5) |
85.2 (65.4-95.1) |
| Poly RF-positive (n=16) |
12.5 (2.2-39.6) |
71.2 (59.3-80.9) |
8.7 (1.5-29.5) |
| Poly RF-negative (n=36) |
28.1 (14.4-47.0) |
75.4 (61.9-85.5) |
39.1 (20.5-61.2) |
| Oligoarthritis (n=24) |
30.4 (14.1-53.0) |
75.8 (63.4-85.1) |
30.4 (14.1-53.0) |
| Systemic-Onset (n=13) |
16.7 (2.9-49.1) |
72.7 (61.2-82.1) |
8.7 (1.5-29.5) |
|
Anti-citrullinated vimentin |
|
|
|
|
Antibodies 1–16 (> 0.79OD) |
|
|
|
| Overall (n=95) |
10.9 (5.6-19.5) |
86.2 (67.4-95.5) |
71.4 (42.0-90.4) |
| Poly RF-positive (n=16) |
6.3 (0.3-32.2) |
88.2 (78.2-94.1) |
10.0 (0.5-45.9) |
| Poly RF-negative (n=36) |
9.1 (2.4-25.5) |
88.1 (76.5-94.7) |
30.0 (8.1-64.6) |
| Oligoarthritis (n=24) |
12.5 (3.3-33.5) |
89.7 (79.3-95.4) |
30.0 (8.1-64.6) |
| Systemic-Onset (n=13) |
23.1 (6.2-54.0) |
91.1 (82.0-96.1) |
30.0 (8.1-64.6) |
|
Anti-citrullinated vimentin |
|
|
|
|
Antibodies 59–74 (> 0.81OD) |
|
|
|
| Overall (n=95) |
7.8 (3.5-15.9) |
89.7 (71.5-97.3) |
70.0 (35.4-91.9) |
| Poly RF-positive (n=16) |
14.3 (2.5-43.8) |
93.4 (84.7-97.6) |
28.6 (5.1-69.7) |
| Poly RF-negative (n=36) |
6.1 (1.1-21.6) |
91.2 (80.0-96.7) |
28.6 (5.1-69.7) |
| Oligoarthritis (n=24) |
8.3 (1.5-28.5) |
92.4 (82.5-97.2) |
28.6 (5.1-69.7) |
| Systemic-Onset (n=13) | 7.7 (0.4-37.9) | 92.2 (83.2-96.8) | 14.3 (0.8-58.0) |
CI: Confidence interval; OD: Optical density; PPV: Positive predictive value; RF: Rheumatoid factor. Subtypes with small sample size were not included in the subtype analysis.